CHMM.F Stock Overview
A clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Chimeric Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.03 |
| 52 Week High | AU$0.035 |
| 52 Week Low | AU$0.013 |
| Beta | 1.72 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -53.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHMM.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 3.2% | 1.7% |
| 1Y | n/a | 6.0% | 26.3% |
Return vs Industry: Insufficient data to determine how CHMM.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CHMM.F performed against the US Market.
Price Volatility
| CHMM.F volatility | |
|---|---|
| CHMM.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CHMM.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CHMM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | Jennifer Chow | www.chimerictherapeutics.com |
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric.
Chimeric Therapeutics Limited Fundamentals Summary
| CHMM.F fundamental statistics | |
|---|---|
| Market cap | US$16.02m |
| Earnings (TTM) | -US$7.60m |
| Revenue (TTM) | US$8.09m |
2.0x
P/S Ratio-2.1x
P/E RatioIs CHMM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHMM.F income statement (TTM) | |
|---|---|
| Revenue | AU$12.47m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$12.47m |
| Other Expenses | AU$24.19m |
| Earnings | -AU$11.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 100.00% |
| Net Profit Margin | -94.06% |
| Debt/Equity Ratio | 0% |
How did CHMM.F perform over the long term?
See historical performance and comparison